Viruses 2009, 1(3), 1209-1239; doi:10.3390/v1031209
Review

Current and Novel Inhibitors of HIV Protease

1,5email, 2,3email, 1,4email and 1,4,5,* email
Received: 8 October 2009; in revised form: 7 December 2009 / Accepted: 7 December 2009 / Published: 11 December 2009
(This article belongs to the Special Issue Retroviral Enzymes)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: The design, development and clinical success of HIV protease inhibitors represent one of the most remarkable achievements of molecular medicine. This review describes all nine currently available FDA-approved protease inhibitors, discusses their pharmacokinetic properties, off-target activities, side-effects, and resistance profiles. The compounds in the various stages of clinical development are also introduced, as well as alternative approaches, aiming at other functional domains of HIV PR. The potential of these novel compounds to open new way to the rational drug design of human viruses is critically assessed.
Keywords: HIV protease; protease inhibitors; HAART; resistance development; pharmacokinetic boosting; protease dimerization; alternative inhibitors
PDF Full-text Download PDF Full-Text [1044 KB, uploaded 11 December 2009 15:35 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Pokorná, J.; Machala, L.; Řezáčová, P.; Konvalinka, J. Current and Novel Inhibitors of HIV Protease. Viruses 2009, 1, 1209-1239.

AMA Style

Pokorná J, Machala L, Řezáčová P, Konvalinka J. Current and Novel Inhibitors of HIV Protease. Viruses. 2009; 1(3):1209-1239.

Chicago/Turabian Style

Pokorná, Jana; Machala, Ladislav; Řezáčová, Pavlína; Konvalinka, Jan. 2009. "Current and Novel Inhibitors of HIV Protease." Viruses 1, no. 3: 1209-1239.


Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert